Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392225 | 0.81 | TSHR (0.51) | MMENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3252245 | 0.81 | GRIK1 (0.51) | GRIK1SMN1; SMN2 | |
| SCHEMBL28014450 | 0.81 | GRIK1 (0.57) | GRIK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4290341 | 0.80 | GRIK1 (0.50) | GRIK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6192793 | 0.80 | GRIK1 (0.50) | GRIK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24252168 | 0.80 | GRIK1 (0.50) | GRIK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17510916 | 0.80 | GRIK1 (0.50) | GRIK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5613518 | 0.79 | MMP12 (0.54) | MMEFDFT1GRIK1 | |
| SCHEMBL27800230 | 0.78 | FDFT1 (0.54) | MMEFDFT1 | |
| SCHEMBL18019606 | 0.78 | FDFT1 (0.54) | MMEFDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |